Publications
-
Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.
SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2
CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Number of citations: 27
-
Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Number of citations: 69
-
Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.
SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.
signal transduction and targeted therapy . 5(1): 14-14. Number of citations: 111
-
Puigoriol-Illamola D, Leiva R, Vazquez M, Vázquez S, Griñán-Ferré C and Pallàs M.
11 beta-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress
MOLECULAR NEUROBIOLOGY . 57(1): 551-565. Number of citations: 10
-
Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vazquez M and Masana L.
Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes
METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 12-21. Number of citations: 37
-
Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vazquez M, Pizarro J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C and Muñoz-Berbel X.
Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients.
BIOSENSORS & BIOELECTRONICS . 136: 38-46. Number of citations: 13
-
Zarei M, Pujol E, Quesada T, Villarroya-Gombau F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.
Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.
BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Number of citations: 14
-
Zarei M, Barroso E, Palomer FX, Escolà-Gil JC, Cedó L, Wahli W and Vazquez M.
Pharmacological PPARß/d activation upregulates VLDLR in hepatocytes.
Clinica e Investigacion en Arteriosclerosis . 31(3): 111-118. Number of citations: 11
-
Busquets O, Eritja À, López BM, Ettcheto M, Manzine PR, Castro-Torres RD, Verdaguer E, Olloquequi J, Vazquez M, Auladell C, Folch J and Camins A.
Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model
JOURNAL OF NEUROCHEMISTRY . 149(2): 255-268. Number of citations: 6
-
Ettcheto M, Sánchez-López E, Gómez-Mínguez Y, Cabrera H, Busquets O, Beas-Zarate C, García ML, Carro E, Casadesus G, Auladell C, Vazquez M, Folch J and Camins A.
Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.
MOLECULAR NEUROBIOLOGY . 55(9): 7327-7339. Number of citations: 24